Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Permethrin-Treated Baby Wraps for the Prevention of Malaria.

Name: Kaimen Rigor review — Permethrin-Treated Baby Wraps for the Prevention of Malaria.
Item: Permethrin-Treated Baby Wraps for the Prevention of Malaria.
Rating: 59
Author: Alpha1

Boyce RM, Shook-Sa BE, Ndizeye R, Baguma E, Giandomenico D, Cassidy CA, Eshun S, Siedner MJ, Staedke SG, Ntaro M, Juliano JJ, Reyes R, Mulogo EM

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 9 high issues for “Permethrin-Treated Baby Wraps for the Prevention of Malaria.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Read alongside

Permethrin-Treated Baby Wraps for the Prevention of Malaria.

Boyce RM, Shook-Sa BE, Ndizeye R, Baguma E, Giandomenico D, Cassidy CA, Eshun S, Siedner MJ, Staedke SG, Ntaro M, Juliano JJ, Reyes R, Mulogo EM

Read full text (PMC)

DOI

10.1056/NEJMoa2501628

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/0a7187f8-a894-4c39-8614-78df4ff526f2" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/0a7187f8-a894-4c39-8614-78df4ff526f2/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 9 high issues for “Permethrin-Treated Baby Wraps for the Prevention of Malaria.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

8e3320c072936f469ad2a6458b8d3abdf680c19124935ccc8dec5a324f154785

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Permethrin-Treated Baby Wraps for the Prevention of Malaria.

Boyce RM, Shook-Sa BE, Ndizeye R, Baguma E, Giandomenico D, Cassidy CA, Eshun S, Siedner MJ, Staedke SG, Ntaro M, Juliano JJ, Reyes R, Mulogo EM

Paper source

Permethrin-Treated Baby Wraps for the Prevention of Malaria.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★
ReportingStatistical analysis partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 304DisclosureReporting gaps 05AvailabilityNone found 06Copyedit10 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper reports a well-conducted RCT with thorough design and transparent reporting, but contains several reporting gaps that reduce reproducibility: missing regulatory compliance statement, missing statistical software identification, unspecified statistical model, and a lack of exact p-values. Minor numerical inconsistencies in baseline tables should be corrected.

All three reviewer runs (from the same model) converged on most dimensions; the two disagreements (ethical approvals, key resources, statistical analysis) were resolved by weighing the checklist-level evidence. The statistics component checked only 2 tests (both consistent); the remaining inferential statistics are unverified. No retracted or fabricated citations were found.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 1 via agent-written checks.

Overstated conclusions

1 finding · worst low

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

9 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

3 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Ethics/consent reporting incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Eight Dimensions5 pass · 3 warn

Prior work is cited to contextualize the need for complementary innovations, including limitations of LLINs, vaccines, and seasonal chemoprevention. The premise that treated wraps could protect during outdoor/daytime biting is logically derived from the evidence. Limitations of prior research (e.g., waning vaccine efficacy in infants, feasibility of seasonal chemoprevention in perennial settings) are acknowledged.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 92% conf

The trial is well grounded in prior literature on ITN/insecticide-treated clothing and clearly links the premise to a testable hypothesis.

Evidence

paraphrase[Introduction]

“Similar approaches have been employed for military uniforms, as well as clothing and blankets for refugees.”

“We hypothesized that treating wraps with repellent might provide an additional layer of protection against malaria.”

IntroductionFind in source

PASSReviewer 2· 95% conf

The paper establishes a clear scientific foundation, citing prior work on malaria burden, insecticide resistance, outdoor biting, and gaps in existing interventions, and provides a logical rationale for the study.

Evidence

paraphrase[Background, paragraph 1-3]

“Paraphrase: The background cites studies on insecticide resistance, outdoor biting, seasonal chemoprevention, and malaria vaccines, noting waning protection and reduced efficacy in infants.”

“We hypothesized that treating wraps with repellent might provide an additional layer of protection against malaria.”

Introduction ¶3Find in source

“Yet existing vaccines are characterized by waning protection and appear to be less effective in infants.”

Introduction ¶2Find in source

PASSReviewer 3· 95% conf

The paper clearly establishes the scientific premise by citing prior research on malaria burden, limitations of existing interventions, and the rationale for treated wraps, and addresses gaps in prior work.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Despite gains, progress against malaria has stalled; insecticide resistance and outdoor biting are cited; seasonal chemoprevention and vaccines have limitations.”

“We hypothesized that treating wraps with repellent might provide an additional layer of protection against malaria.”

Introduction ¶4Find in source

paraphrase[Introduction, paragraph 3]

“Existing vaccines characterized by waning protection and less effective in infants; seasonal chemoprevention feasibility uncertain in perennial transmission.”

Randomization was performed using REDCap with a permuted block design, stratified by age and site. The trial is described as double-blind, with blinding of participants and clinicians; the distinct odor of permethrin is acknowledged as a potential limitation. A power analysis justified the sample size of 400 pairs. Inclusion/exclusion criteria are clearly stated. The analysis follows an intention-to-treat approach with censoring for recurrent infections.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 93% conf

Core design elements are reported and adequate for a human RCT: randomization, blinding, power analysis, and inclusion/exclusion criteria are all described.

Evidence

“Randomization was stratified by age of the child (age 6–11 months and 12–18 months) and clinical site, using a permuted block design.”

MethodsFind in source

“A total of 400 mother-infant pairs (200 per arm) were required to detect a 30% reduction in the incidence of clinical malaria (i.e., incidence rate ratio [IRR]=0.70) in the permethrin-treated arm relative to the sham-treated arm over the 24-week study period with a two-sided test, power of 0.80, and type I error 0.05.”

Statistical analysisFind in source

“Study participants and clinicians remained blinded to the study allocation.”

MethodsFind in source

PASSReviewer 2· 95% conf

The study design is rigorous for a human RCT: randomization method, blinding, power analysis, inclusion/exclusion criteria are all adequately reported.

Evidence

“Randomization was stratified by age of the child (age 6–11 months and 12–18 months) and clinical site, using a permuted block design. Randomization was performed on-site by a research assistant using REDCap.”

Methods ¶3Find in source

paraphrase[Methods, paragraph 4 and Discussion]

“Study participants and clinicians remained blinded to the study allocation. ...permethrin does have a distinct odor which could not be blinded.”

Statistical analysisFind in source

PASSReviewer 3· 95% conf

The study design is rigorous: randomization method, unit, blinding, power analysis, inclusion/exclusion criteria, and pre-specified analysis population are all adequately reported.

Evidence

MethodsFind in source

“Study participants and clinicians remained blinded to the study allocation.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“A total of 400 mother-infant pairs (200 per arm) were required to detect a 30% reduction in the incidence of clinical malaria... with a two-sided test, power of 0.80, and type I error 0.05.”

All applicable sub-criteria are reported and adequate. Sex of children is reported in Table 1 (47% female in sham, 49% in permethrin). Age, weight (MUAC), and health status (hemoglobin, malaria status) are detailed. Demographics include maternal age, education, household characteristics, and travel time. Sex justification is not applicable as both sexes are included.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Sex, age, weight/nutritional status, and demographic characteristics are reported for the human participants.

Evidence

“Female | 94 (47.0) | 98 (49.0) | | Age in months (Median (Q1, Q3)) | 11.0 (8.0, 14.0) | 12.0 (8.0, 15.0)”

Table 1Find in source

“MUAC in cm (Median (Q1, Q3)) | 14.3 (13.8, 15.1) | 14.3 (13.6, 15.2)”

Table 1Find in source

PASSReviewer 2· 90% conf

Biological variables are adequately reported for a human trial: sex, age, health status, and demographics are provided.

Evidence

“Female | 94 (47.0) | 98 (49.0)”

Table 1Find in source

paraphrase[Table 1 and Methods]

“Paraphrase: Table 1 includes age in months, MUAC, hemoglobin, and baseline malaria test results.”

paraphrase[Table 1]

“Paraphrase: Table 1 includes maternal age, education, parity, place of birth, household characteristics (floor material, water source, livestock, etc.).”

PASSReviewer 3· 95% conf

Biological variables for human subjects are adequately reported: child's sex, age, MUAC, hemoglobin, and maternal demographics are provided.

Evidence

paraphrase[Table 1]

“Female 94 (47.0%) [sham], 98 (49.0%) [permethrin]”

paraphrase[Table 1]

“Age in months, MUAC in cm, and hemoglobin in g/dL are shown with medians and quartiles.”

paraphrase[Table 1]

“Maternal age, parity, education, place of birth, household members, floor material, water source, etc., are listed.”

The trial was approved by three named ethics bodies (WCG IRB, Mbarara University REC, Uganda National Council for Science and Technology). Written informed consent from mothers is stated. However, the paper does not explicitly state compliance with the Declaration of Helsinki, ICH-GCP, or other regulatory frameworks, which is required for a human trial. The adherence to CONSORT guidelines is a reporting standard, not a regulatory compliance statement.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceNOT REPORTED

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Named ethics bodies approved the trial and written informed consent was obtained.

Evidence

“The trial was approved by the WCG Institutional Review Board, the Mbarara University of Science and Technology Research Ethics Committee, and the Uganda National Council of Science and Technology.”

MethodsFind in source

“Written informed consent was obtained from the mother.”

MethodsFind in source

WARNReviewer 2· 90% conf

Ethical approval and informed consent are explicitly reported, but a statement of regulatory compliance with a recognized framework is missing.

Evidence

Methods ¶1Find in source

“Written informed consent was obtained from the mother.”

Methods ¶1Find in source

absence[Methods, paragraph 1 and throughout]

No explicit statement of compliance with Declaration of Helsinki or ICH-GCP is present.

WARNReviewer 3· 90% conf

Ethics approval and informed consent are adequately reported, but a statement of regulatory compliance (e.g., Declaration of Helsinki) is missing.

Evidence

MethodsFind in source

“Written informed consent was obtained from the mother.”

MethodsFind in source

absence[Methods, Study Design and throughout]

No statement of adherence to a regulatory framework (e.g., Declaration of Helsinki) is found.

The permethrin is identified by manufacturer (Sawyer Products), dilution (0.5%), and treatment procedure. The bed net (PermaNet 2.0, Vestergaard) is also identified. However, the statistical software (e.g., SAS, R, Stata) used for the primary analysis is not mentioned, which is a key resource for reproducibility. Other sub-criteria (antibodies, cell lines, mycoplasma, organisms) are not applicable to this clinical trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 88% conf

The investigational product (permethrin-treated wraps) and the LLIN are identified with manufacturer, formulation, and regimen; REDCap is named.

Evidence

paraphrase[Methods, Interventions]

“Wraps were soaked in permethrin diluted to 0.5% in accordance with the manufacturer's instructions (Sawyer Products, Safety Harbor, FL)”

“All participants received a new, pyrethroid-only LLIN (PermaNet 2.0, Vestergaard).”

MethodsFind in source

WARNReviewer 2· 80% conf

The investigational product (permethrin) is adequately identified, but the statistical software used for analysis is not reported.

Evidence

“Wraps were soaked in permethrin diluted to 0.5% in accordance with the manufacturer’s instructions (Sawyer Products, Safety Harbor, FL)”

Methods ¶4Find in source

“All participants received a new, pyrethroid-only LLIN (PermaNet 2.0, Vestergaard).”

Methods ¶4Find in source

absence[Methods, Statistical analysis]

Statistical software not identified in the main text.

WARNReviewer 3· 85% conf

The investigational product (permethrin and wraps) is adequately identified, but the statistical software used for analysis is not reported.

Evidence

“Wraps were soaked in permethrin diluted to 0.5% in accordance with the manufacturer’s instructions (Sawyer Products, Safety Harbor, FL)”

MethodsFind in source

“All participants received a new, pyrethroid-only LLIN (PermaNet 2.0, Vestergaard).”

MethodsFind in source

absence[Methods, Statistical analysis and throughout]

Statistical software for analysis is not reported.

The primary outcome is reported with IRR (0.34, 95% CI 0.23-0.51) and IRD, and cumulative incidence curves are shown. However, the paper does not name the specific model (e.g., Poisson regression) used to estimate the IRR, nor does it discuss verification of model assumptions. The p-value is reported as '<0.001' rather than exact. Statistical software is not identified. Data presentation meets clinical trial standards (tables with CIs, CONSORT diagram, Kaplan-Meier-like curves). Mathematical plausibility checks on reported incidence rates are consistent.

Sub-criteria

tests namedINADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedNOT REPORTED

mathematical plausibilityPASS

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

Primary and secondary analyses use named tests with effect sizes and confidence intervals; the primary p-value is reported as a threshold (p<0.001) and analysis software is not named.

Evidence

“Clinical malaria incidence was 2.14 (95% CI 1.73–2.62) and 0.73 (95% CI 0.51–1.02) per 100 person weeks in the sham-treated and permethrin-treated arms, respectively (incidence rate ratio 0.34, 95% CI 0.23–0.51, p<0.001).”

AbstractFind in source

“Incidence rates of clinical P. falciparum malaria in children over the 24-week follow-up period were calculated by arm and compared by estimating the IRR and incidence rate difference (IRD) with adjustments for stratification variables.”

Statistical analysisFind in source

WARNReviewer 2· 85% conf

Effect sizes with confidence intervals and data presentation are adequate, but the specific statistical test is not named, assumptions are not verified, p-values are not exact, and software is not identified.

Evidence

paraphrase[Methods, Statistical analysis]

“A detailed description of the statistical methods is provided in the Supplementary Appendix.”

“incidence rate ratio 0.34, 95% CI 0.23–0.51, p<0.001”

Results ¶2Find in source

“Clinical malaria incidence (per 100 person-weeks) | 2.14 (1.73, 2.62) | 0.73 (0.51, 1.02) | −1.41 (−2.03, −0.83) | 0.34 (0.23, 0.51)”

Table 2Find in source

WARNReviewer 3· 85% conf

Effect sizes with confidence intervals and data presentation are adequate, but the specific statistical test is not named, assumptions are not verified, exact p-values are not provided, and statistical software is not identified.

Evidence

Statistical analysisFind in source

absence[Methods, Statistical analysis]

Assumptions are not verified.

paraphrase[Results, Primary Outcome]

“p<0.001”

The data-availability statement names a concrete route (DE-identified individual data shared 9–36 months post-publication after IRB/REB approval and a data use/sharing agreement with UNC), which meets the managed-access standard. Repository deposit and accession numbers are n/a for identifiable patient-level data; no bespoke public code repository is mentioned.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

A concrete managed-access data-sharing statement is provided; repository deposit and accession numbers are n/a for identifiable patient data.

Evidence

“Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

A data availability statement is present with a concrete access mechanism via data use agreement with UNC, which is appropriate for patient-level data.

Evidence

Data availabilityFind in source

PASSReviewer 3· 90% conf

A data availability statement with a concrete access route (managed access via UNC with conditions) is provided, and code sharing is not applicable as no custom code is mentioned.

Evidence

Data availabilityFind in source

Trial is registered (NCT05391230), CONSORT adherence is stated, detailed methods are given, and limitations are candidly discussed (single site, self-reported LLIN/wash use, blinding compromise by permethrin odor). Null/contrary secondary results (growth Z-scores) are reported transparently. Funding and grant numbers are disclosed; some secondary/molecular outcomes are deferred to separate reports, which is disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedINADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 92% conf

The manuscript reports thoroughly: registration, CONSORT adherence, funding/COI, limitations, and proportional conclusions.

Evidence

“This report adheres to the guidelines for Consolidated Standards of Reporting Trials.”

MethodsFind in source

“ClinicalTrials.gov (http://ClinicalTrials.gov) NCT05391230”

AbstractFind in source

“Funding for the trial was provided by a Clinical Scientist Development Award to RMB from the Doris Duke Foundation (Award 24971).”

FundingFind in source

PASSReviewer 2· 90% conf

Reporting is transparent overall: methods are complete, trial is registered, reporting guideline is followed, limitations are discussed, and conclusions are proportional. However, not all secondary outcomes are reported in this paper, and a conflict of interest statement is missing.

Evidence

“ClinicalTrials.gov (http://ClinicalTrials.gov) NCT05391230 (https://clinicaltrials.gov/ct2/show/NCT05391230)”

AbstractFind in source

“Molecular testing for asymptomatic parasitemia and analysis of maternal outcomes is ongoing and will be reported separately.”

MethodsFind in source

absence[Funding section and end of manuscript]

No explicit conflict of interest statement is present.

PASSReviewer 3· 90% conf

Most reporting transparency criteria are met: methods are complete, trial is registered, reporting guideline is followed, limitations are discussed, and conclusions are proportional. However, not all pre-specified outcomes are reported in this paper (some are pending), and a conflicts-of-interest statement is absent.

Evidence

“ClinicalTrials.gov (http://ClinicalTrials.gov) NCT05391230”

AbstractFind in source

“Molecular testing for asymptomatic parasitemia and analysis of maternal outcomes is ongoing and will be reported separately.”

MethodsFind in source

absence[Acknowledgements and throughout]

No conflicts-of-interest statement is found.

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 30 references by DOI: 22 verified — 8 no DOI (shown, not verified).

3 data/code links checked; 2 live.

Copyediting

10 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 10 minor suggestions below.

10 copyedit issues flagged: mostly consistency, other, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

This published paper is robust in its core design and primary findings, but an informed reader should note the missing regulatory compliance statement, unspecified statistical software, and unreported model assumptions as limitations. The authors should consider issuing a correction for the baseline numerical errors (mRDT percentages, MUAC category percentages) and adding a conflicts-of-interest statement. The reported effect size is large and consistent with the recomputed incidence rates, so the overall conclusion is likely trustworthy.

1.
HIGHethics
Issue a correction to add a statement of regulatory compliance (e.g., 'The trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP') to the Methods section.
A human clinical trial must explicitly state adherence to recognized ethical standards; its absence is a regulatory reporting gap.
2.
HIGHreporting
Issue a correction to add a formal conflicts-of-interest statement for all authors (e.g., 'The authors declare no competing interests') in the Acknowledgements or a dedicated section.
The paper currently discloses funding but no COI statement; this is a standard journal requirement for published research.
3.
HIGHrigor
Issue a correction to correct the baseline mRDT-positive percentages in the Results text (currently 10.7% and 10.1%) to match Table 1 values (10.5% and 10.0%).
The in-text percentages are arithmetically inconsistent with the counts (21/200=10.5%, 20/200=10.0%); this is a factual error that could mislead readers.
4.
HIGHrigor
Issue a correction to correct the permethrin-arm MUAC category percentages in Table 1 (currently 19.0% and 82.0%) to the exact values (18.5% and 81.5%) so the column sums to 100%.
The reported percentages sum to 101% and are inconsistent with the counts (37/200=18.5%, 163/200=81.5%); this is a minor data error that should be corrected.
5.
HIGHstatistics
Issue a correction to identify the name and version of the statistical software used for analysis (e.g., R 4.2, Stata 17, SAS 9.4) in the Statistical analysis section.
Reproducibility requires knowing the software environment; this is a standard reporting expectation for clinical trials.
6.
HIGHstatistics
Issue a correction to name the specific statistical model used to estimate the incidence rate ratio (e.g., Poisson regression, negative binomial regression) in the Statistical analysis section.
The current description ('estimating the IRR with adjustments for stratification variables') is ambiguous; naming the model is essential for reproducibility.
7.
HIGHstatistics
Report an exact p-value for the primary IRR (e.g., p=0.0002) instead of the threshold 'p<0.001' in the Results section, or state that the p-value is reported as a threshold per journal policy.
Exact p-values allow readers to assess the strength of evidence more precisely; thresholds are considered less informative.
8.
HIGHstatistics
Add a brief description of assumption verification for the primary analysis (e.g., 'The proportional hazards assumption was tested using Schoenfeld residuals') or explain why standard methods are appropriate.
Model assumptions are critical for validity; their absence reduces confidence in the reported effect estimates.
9.
HIGHreporting
In the Discussion, explicitly note that molecular testing for asymptomatic parasitemia and maternal outcomes are deferred to separate reports, and reference the protocol or registration for the full list of outcomes.
Transparency requires clear acknowledgment of incomplete outcome reporting; this is already stated but could be made more explicit for readers.
10.
MEDIUMcopyedit
Remove apparent OCR artifacts ('pmc 1', '393 14 497471 1399 1408') from the manuscript header and abstract.
These are formatting errors from PDF extraction that should not appear in the published version.
11.
MEDIUMcopyedit
Fix the typo 'Level IIl Health Centres' to 'Level III Health Centres' in the Acknowledgements.
Lowercase 'l' used instead of uppercase 'I' in the roman numeral is a typographical error.
12.
MEDIUMcopyedit
Complete the incomplete sentence in Methods, Study Design: 'The trial design and protocols have been published and are included in the .' should be '...are included in the Supplementary Appendix.'
The sentence ends abruptly, leaving a missing reference.
13.
MEDIUMcopyedit
Remove the empty parentheses '()' in Methods, Interventions: '...and allowed to dry ().'
Empty parentheses are a placeholder that should be removed or completed.
14.
LOWother
Consider adding a note in the Acknowledgements that the provision of permethrin by Sawyer Products does not constitute an endorsement or conflict of interest.
Product donation could be perceived as a conflict; a formal statement would clarify this.

Full text (28,292 chars)Analyzed: Aug 10, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Permethrin-Treated Baby Wraps for the Prevention of Malaria.

Boyce RM, Shook-Sa BE, Ndizeye R, Baguma E, Giandomenico D, Cassidy CA, Eshun S, Siedner MJ, Staedke SG, Ntaro M, Juliano JJ, Reyes R, Mulogo EM

Read full text (PMC)

DOI

10.1056/NEJMoa2501628

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/0a7187f8-a894-4c39-8614-78df4ff526f2" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/0a7187f8-a894-4c39-8614-78df4ff526f2/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 9 high issues for “Permethrin-Treated Baby Wraps for the Prevention of Malaria.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

8e3320c072936f469ad2a6458b8d3abdf680c19124935ccc8dec5a324f154785

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★
ReportingStatistical analysis partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 304DisclosureReporting gaps 05AvailabilityNone found 06Copyedit10 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 1 via agent-written checks.

Overstated conclusions

1 finding · worst low

Conclusions only partially backed by the presented evidenceAssessed

9 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

3 findings · worst high

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Ethics/consent reporting incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Eight Dimensions5 pass · 3 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 92% conf

The trial is well grounded in prior literature on ITN/insecticide-treated clothing and clearly links the premise to a testable hypothesis.

Evidence

paraphrase[Introduction]

“Similar approaches have been employed for military uniforms, as well as clothing and blankets for refugees.”

“We hypothesized that treating wraps with repellent might provide an additional layer of protection against malaria.”

IntroductionFind in source

PASSReviewer 2· 95% conf

Evidence

paraphrase[Background, paragraph 1-3]

“Paraphrase: The background cites studies on insecticide resistance, outdoor biting, seasonal chemoprevention, and malaria vaccines, noting waning protection and reduced efficacy in infants.”

“We hypothesized that treating wraps with repellent might provide an additional layer of protection against malaria.”

Introduction ¶3Find in source

“Yet existing vaccines are characterized by waning protection and appear to be less effective in infants.”

Introduction ¶2Find in source

PASSReviewer 3· 95% conf

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Despite gains, progress against malaria has stalled; insecticide resistance and outdoor biting are cited; seasonal chemoprevention and vaccines have limitations.”

“We hypothesized that treating wraps with repellent might provide an additional layer of protection against malaria.”

Introduction ¶4Find in source

paraphrase[Introduction, paragraph 3]

“Existing vaccines characterized by waning protection and less effective in infants; seasonal chemoprevention feasibility uncertain in perennial transmission.”

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 93% conf

Core design elements are reported and adequate for a human RCT: randomization, blinding, power analysis, and inclusion/exclusion criteria are all described.

Evidence

“Randomization was stratified by age of the child (age 6–11 months and 12–18 months) and clinical site, using a permuted block design.”

MethodsFind in source

Statistical analysisFind in source

“Study participants and clinicians remained blinded to the study allocation.”

MethodsFind in source

PASSReviewer 2· 95% conf

The study design is rigorous for a human RCT: randomization method, blinding, power analysis, inclusion/exclusion criteria are all adequately reported.

Evidence

Methods ¶3Find in source

paraphrase[Methods, paragraph 4 and Discussion]

“Study participants and clinicians remained blinded to the study allocation. ...permethrin does have a distinct odor which could not be blinded.”

Statistical analysisFind in source

PASSReviewer 3· 95% conf

The study design is rigorous: randomization method, unit, blinding, power analysis, inclusion/exclusion criteria, and pre-specified analysis population are all adequately reported.

Evidence

MethodsFind in source

“Study participants and clinicians remained blinded to the study allocation.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“A total of 400 mother-infant pairs (200 per arm) were required to detect a 30% reduction in the incidence of clinical malaria... with a two-sided test, power of 0.80, and type I error 0.05.”

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Sex, age, weight/nutritional status, and demographic characteristics are reported for the human participants.

Evidence

“Female | 94 (47.0) | 98 (49.0) | | Age in months (Median (Q1, Q3)) | 11.0 (8.0, 14.0) | 12.0 (8.0, 15.0)”

Table 1Find in source

“MUAC in cm (Median (Q1, Q3)) | 14.3 (13.8, 15.1) | 14.3 (13.6, 15.2)”

Table 1Find in source

PASSReviewer 2· 90% conf

Biological variables are adequately reported for a human trial: sex, age, health status, and demographics are provided.

Evidence

“Female | 94 (47.0) | 98 (49.0)”

Table 1Find in source

paraphrase[Table 1 and Methods]

“Paraphrase: Table 1 includes age in months, MUAC, hemoglobin, and baseline malaria test results.”

paraphrase[Table 1]

“Paraphrase: Table 1 includes maternal age, education, parity, place of birth, household characteristics (floor material, water source, livestock, etc.).”

PASSReviewer 3· 95% conf

Biological variables for human subjects are adequately reported: child's sex, age, MUAC, hemoglobin, and maternal demographics are provided.

Evidence

paraphrase[Table 1]

“Female 94 (47.0%) [sham], 98 (49.0%) [permethrin]”

paraphrase[Table 1]

“Age in months, MUAC in cm, and hemoglobin in g/dL are shown with medians and quartiles.”

paraphrase[Table 1]

“Maternal age, parity, education, place of birth, household members, floor material, water source, etc., are listed.”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceNOT REPORTED

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Named ethics bodies approved the trial and written informed consent was obtained.

Evidence

MethodsFind in source

“Written informed consent was obtained from the mother.”

MethodsFind in source

WARNReviewer 2· 90% conf

Ethical approval and informed consent are explicitly reported, but a statement of regulatory compliance with a recognized framework is missing.

Evidence

Methods ¶1Find in source

“Written informed consent was obtained from the mother.”

Methods ¶1Find in source

absence[Methods, paragraph 1 and throughout]

No explicit statement of compliance with Declaration of Helsinki or ICH-GCP is present.

WARNReviewer 3· 90% conf

Ethics approval and informed consent are adequately reported, but a statement of regulatory compliance (e.g., Declaration of Helsinki) is missing.

Evidence

MethodsFind in source

“Written informed consent was obtained from the mother.”

MethodsFind in source

absence[Methods, Study Design and throughout]

No statement of adherence to a regulatory framework (e.g., Declaration of Helsinki) is found.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 88% conf

The investigational product (permethrin-treated wraps) and the LLIN are identified with manufacturer, formulation, and regimen; REDCap is named.

Evidence

paraphrase[Methods, Interventions]

“Wraps were soaked in permethrin diluted to 0.5% in accordance with the manufacturer's instructions (Sawyer Products, Safety Harbor, FL)”

“All participants received a new, pyrethroid-only LLIN (PermaNet 2.0, Vestergaard).”

MethodsFind in source

WARNReviewer 2· 80% conf

The investigational product (permethrin) is adequately identified, but the statistical software used for analysis is not reported.

Evidence

“Wraps were soaked in permethrin diluted to 0.5% in accordance with the manufacturer’s instructions (Sawyer Products, Safety Harbor, FL)”

Methods ¶4Find in source

“All participants received a new, pyrethroid-only LLIN (PermaNet 2.0, Vestergaard).”

Methods ¶4Find in source

absence[Methods, Statistical analysis]

Statistical software not identified in the main text.

WARNReviewer 3· 85% conf

The investigational product (permethrin and wraps) is adequately identified, but the statistical software used for analysis is not reported.

Evidence

“Wraps were soaked in permethrin diluted to 0.5% in accordance with the manufacturer’s instructions (Sawyer Products, Safety Harbor, FL)”

MethodsFind in source

“All participants received a new, pyrethroid-only LLIN (PermaNet 2.0, Vestergaard).”

MethodsFind in source

absence[Methods, Statistical analysis and throughout]

Statistical software for analysis is not reported.

Sub-criteria

tests namedINADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedNOT REPORTED

mathematical plausibilityPASS

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

Primary and secondary analyses use named tests with effect sizes and confidence intervals; the primary p-value is reported as a threshold (p<0.001) and analysis software is not named.

Evidence

AbstractFind in source

Statistical analysisFind in source

WARNReviewer 2· 85% conf

Evidence

paraphrase[Methods, Statistical analysis]

“A detailed description of the statistical methods is provided in the Supplementary Appendix.”

“incidence rate ratio 0.34, 95% CI 0.23–0.51, p<0.001”

Results ¶2Find in source

“Clinical malaria incidence (per 100 person-weeks) | 2.14 (1.73, 2.62) | 0.73 (0.51, 1.02) | −1.41 (−2.03, −0.83) | 0.34 (0.23, 0.51)”

Table 2Find in source

WARNReviewer 3· 85% conf

Evidence

Statistical analysisFind in source

absence[Methods, Statistical analysis]

Assumptions are not verified.

paraphrase[Results, Primary Outcome]

“p<0.001”

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

A concrete managed-access data-sharing statement is provided; repository deposit and accession numbers are n/a for identifiable patient data.

Evidence

Data availabilityFind in source

PASSReviewer 2· 90% conf

A data availability statement is present with a concrete access mechanism via data use agreement with UNC, which is appropriate for patient-level data.

Evidence

Data availabilityFind in source

PASSReviewer 3· 90% conf

A data availability statement with a concrete access route (managed access via UNC with conditions) is provided, and code sharing is not applicable as no custom code is mentioned.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedINADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 92% conf

The manuscript reports thoroughly: registration, CONSORT adherence, funding/COI, limitations, and proportional conclusions.

Evidence

“This report adheres to the guidelines for Consolidated Standards of Reporting Trials.”

MethodsFind in source

“ClinicalTrials.gov (http://ClinicalTrials.gov) NCT05391230”

AbstractFind in source

“Funding for the trial was provided by a Clinical Scientist Development Award to RMB from the Doris Duke Foundation (Award 24971).”

FundingFind in source

PASSReviewer 2· 90% conf

Evidence

“ClinicalTrials.gov (http://ClinicalTrials.gov) NCT05391230 (https://clinicaltrials.gov/ct2/show/NCT05391230)”

AbstractFind in source

“Molecular testing for asymptomatic parasitemia and analysis of maternal outcomes is ongoing and will be reported separately.”

MethodsFind in source

absence[Funding section and end of manuscript]

No explicit conflict of interest statement is present.

PASSReviewer 3· 90% conf

Evidence

“ClinicalTrials.gov (http://ClinicalTrials.gov) NCT05391230”

AbstractFind in source

“Molecular testing for asymptomatic parasitemia and analysis of maternal outcomes is ongoing and will be reported separately.”

MethodsFind in source

absence[Acknowledgements and throughout]

No conflicts-of-interest statement is found.

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 30 references by DOI: 22 verified — 8 no DOI (shown, not verified).

3 data/code links checked; 2 live.

Copyediting

10 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 10 minor suggestions below.

10 copyedit issues flagged: mostly consistency, other, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHethics
Issue a correction to add a statement of regulatory compliance (e.g., 'The trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP') to the Methods section.
A human clinical trial must explicitly state adherence to recognized ethical standards; its absence is a regulatory reporting gap.
2.
HIGHreporting
Issue a correction to add a formal conflicts-of-interest statement for all authors (e.g., 'The authors declare no competing interests') in the Acknowledgements or a dedicated section.
The paper currently discloses funding but no COI statement; this is a standard journal requirement for published research.
3.
HIGHrigor
Issue a correction to correct the baseline mRDT-positive percentages in the Results text (currently 10.7% and 10.1%) to match Table 1 values (10.5% and 10.0%).
The in-text percentages are arithmetically inconsistent with the counts (21/200=10.5%, 20/200=10.0%); this is a factual error that could mislead readers.
4.
HIGHrigor
Issue a correction to correct the permethrin-arm MUAC category percentages in Table 1 (currently 19.0% and 82.0%) to the exact values (18.5% and 81.5%) so the column sums to 100%.
The reported percentages sum to 101% and are inconsistent with the counts (37/200=18.5%, 163/200=81.5%); this is a minor data error that should be corrected.
5.
HIGHstatistics
Issue a correction to identify the name and version of the statistical software used for analysis (e.g., R 4.2, Stata 17, SAS 9.4) in the Statistical analysis section.
Reproducibility requires knowing the software environment; this is a standard reporting expectation for clinical trials.
6.
HIGHstatistics
Issue a correction to name the specific statistical model used to estimate the incidence rate ratio (e.g., Poisson regression, negative binomial regression) in the Statistical analysis section.
The current description ('estimating the IRR with adjustments for stratification variables') is ambiguous; naming the model is essential for reproducibility.
7.
HIGHstatistics
Report an exact p-value for the primary IRR (e.g., p=0.0002) instead of the threshold 'p<0.001' in the Results section, or state that the p-value is reported as a threshold per journal policy.
Exact p-values allow readers to assess the strength of evidence more precisely; thresholds are considered less informative.
8.
HIGHstatistics
Add a brief description of assumption verification for the primary analysis (e.g., 'The proportional hazards assumption was tested using Schoenfeld residuals') or explain why standard methods are appropriate.
Model assumptions are critical for validity; their absence reduces confidence in the reported effect estimates.
9.
HIGHreporting
In the Discussion, explicitly note that molecular testing for asymptomatic parasitemia and maternal outcomes are deferred to separate reports, and reference the protocol or registration for the full list of outcomes.
Transparency requires clear acknowledgment of incomplete outcome reporting; this is already stated but could be made more explicit for readers.
10.
MEDIUMcopyedit
Remove apparent OCR artifacts ('pmc 1', '393 14 497471 1399 1408') from the manuscript header and abstract.
These are formatting errors from PDF extraction that should not appear in the published version.
11.
MEDIUMcopyedit
Fix the typo 'Level IIl Health Centres' to 'Level III Health Centres' in the Acknowledgements.
Lowercase 'l' used instead of uppercase 'I' in the roman numeral is a typographical error.
12.
MEDIUMcopyedit
Complete the incomplete sentence in Methods, Study Design: 'The trial design and protocols have been published and are included in the .' should be '...are included in the Supplementary Appendix.'
The sentence ends abruptly, leaving a missing reference.
13.
MEDIUMcopyedit
Remove the empty parentheses '()' in Methods, Interventions: '...and allowed to dry ().'
Empty parentheses are a placeholder that should be removed or completed.
14.
LOWother
Consider adding a note in the Acknowledgements that the provision of permethrin by Sawyer Products does not constitute an endorsement or conflict of interest.
Product donation could be perceived as a conflict; a formal statement would clarify this.

Full text (28,292 chars)Analyzed: Aug 10, 2026